期刊文献+

急性白血病Janus激酶-信号传导和转录激活因子信号通路相关基因突变研究进展

Research progress of Janus kinase-signal transduction and activator of transcription signaling pathway related gene mutations in acute leukemia
原文传递
导出
摘要 在白血病细胞中普遍存在着Janus激酶(Janus kinase,JAK)-信号传导和转录激活因子(signal transduction and activator of transcription,STAT)信号通路的持续激活,该通路在急性白血病(acute leukemia,AL)中占据了重要地位。JAK2/JAK1基因突变在急性髓系白血病和急性淋巴细胞白血病中均有发现,并可能对疾病治疗和总体预后存在影响。在STAT家族成员中,STAT3和STAT5被证明是AL的关键影响因素。这些基因突变都可能为AL的治疗提供新靶点与新思路。该文就有关JAK-STAT信号通路及相关基因突变与AL的研究进展作一综述。 Continuous activation of Janus kinase(JAK)-signal transduction and activator of transcription(STAT)signaling pathway is prevalent in leukemia cells,and it has been found that this pathway plays an important role in acute leukemia(AL).JAK2/JAK1 gene mutations are found in both acute myelocytic leukemia and acute lymphoblastic leukemia and may have implications for the treatment and overall prognosis of the disease.Among the STAT family members,STAT3 and STAT5 proved to be key factors in AL.These gene mutations may provide new targets and new ideas for the treatment of AL.This article provides a review of the research progress of JAK-STAT signaling pathway,related gene mutations and AL.
作者 黄诗晋 杨洁 徐晓燕 刘净悦 HUANG Shijin;YANG Jie;XU Xiaoyan;LIU Jingyue(Graduate School,Hebei North University,Zhangjiakou,Hebei 075000,P.R.China;Department of Hematology,Hebei General Hospital,Shijiazhuang,Hebei 050051,P.R.China;Department of Hematology,South District of the Fifth Medical Center of PLA General Hospital,Beijing 100071,P.R.China)
出处 《华西医学》 CAS 2024年第8期1308-1313,共6页 West China Medical Journal
基金 河北省卫生健康委员会指导课题(20200727)。
关键词 Janus激酶-信号传导和转录激活因子信号通路 急性白血病 SH2B衔接蛋白3 Janus kinase-signal transduction and activator of transcription signaling pathway acute leukemia SH2B3
  • 相关文献

参考文献11

二级参考文献52

  • 1顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:473
  • 2费海荣,张日,陈苏宁,潘金兰,岑建农,薛永权.骨髓增殖性疾病137例患者JAK2基因突变的研究[J].中华内科杂志,2007,46(4):271-273. 被引量:15
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myelopreliferative disorders. Lancet, 2005, 365 : 1054-1061. 被引量:1
  • 4James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature, 2005, 434 : 1144-1148. 被引量:1
  • 5Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7:387-397. 被引量:1
  • 6Frohling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2V617F mutation in AML subtypes MS, M6, and M7. Blood, 2006, 107:1242-1243. 被引量:1
  • 7Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene, 2006, 25 : 1434-1436. 被引量:1
  • 8Schnittger S, Bacher U, Kern W, et al. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8 ;21 ) : a comparative study on 1103 CMPD and 269 AML cases. Leukemia, 2007, 21:1843-1845. 被引量:1
  • 9lllmer T, Schaich M, Ehninger G, et al. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica, 2007, 92 : 137-138. 被引量:1
  • 10Levine RL, Lorianx M, Hantly BJP, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 2005, 106:3377-3379. 被引量:1

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部